• Salinomycin: Polyether Ionophore Antibiotic in HCC Research

  2026-07-24

  Salinomycin is advancing hepatocellular carcinoma research by offering mechanistic selectivity and reproducible anti-cancer performance. Discover applied workflows, critical protocol parameters, and troubleshooting strategies to maximize data quality and translational relevance.

• BMS-777607: c-Met Inhibitor for Platelet & Cancer Research

  2026-07-23

  BMS-777607 unlocks advanced workflows in both hiPSC-derived platelet differentiation and cancer metastasis modeling, delivering highly selective MET pathway inhibition for reproducible, high-yield results. Learn how protocol optimization and troubleshooting with this APExBIO compound can streamline your research and minimize technical setbacks.

• Isoprenaline Hydrochloride: Precision in Cardiac and Heart-B

  2026-07-23

  Isoprenaline Hydrochloride (isoproterenol) enables robust modeling of cardiac arrhythmias and the heart-brain axis, uniquely bridging cardiovascular and neurobehavioral research. This guide demystifies advanced workflows, delivers troubleshooting strategies, and translates new insights from reference studies into actionable protocols for scientists.

• CLK2 Kinase Drives Platinum Resistance in Ovarian Cancer

  2026-07-22

  This study identifies Cdc2-like kinase 2 (CLK2) as a pivotal mediator of platinum resistance in ovarian cancer via BRCA1 phosphorylation and enhanced DNA repair. The findings clarify a key mechanism underlying chemoresistance and present CLK2 as a potential therapeutic target to improve treatment outcomes.

• Rapamycin (Sirolimus): Protocols & Innovations for mTOR Inhi

  2026-07-22

  Rapamycin (Sirolimus) is a gold-standard mTOR inhibitor enabling precise modulation of cell growth, immunological responses, and disease modeling. This article bridges advanced research findings with practical workflows—highlighting troubleshooting tips and protocol enhancements for reliable, reproducible results across cancer, mitochondrial, and pulmonary fibrosis studies.

• Epidermal Growth Factor (EGF), Human Recombinant: Functional

  2026-07-21

  Unlock the biological precision of recombinant human EGF in advanced cell signaling and synthetic lethality assays. Discover how EGF’s mechanistic role in EGFR binding and mucosal healing uniquely positions it for innovative cancer research and beyond.

• ATP as a Mechanistic Lever in Mitochondrial Metabolic Regula

  2026-07-21

  This thought-leadership article explores how Adenosine Triphosphate (ATP) enables next-generation mechanistic studies in mitochondrial metabolism, with a focus on the translational potential emerging from new insights into post-translational enzyme regulation. Drawing from recent breakthroughs, including the discovery of TCAIM’s targeted modulation of OGDH in the TCA cycle, the article provides a framework for researchers to strategically deploy ATP in advanced metabolic, signaling, and translational workflows. The piece differentiates itself by bridging molecular mechanism with application, emphasizing protocol considerations and the competitive landscape for ATP reagents.

• YM-155 Hydrochloride: Potent Survivin Inhibitor for Cancer R

  2026-07-20

  YM-155 hydrochloride is a highly selective small-molecule survivin inhibitor that demonstrates nanomolar potency in suppressing tumor cell proliferation. Its distinct mechanism and validated efficacy make it pivotal for apoptosis inhibitor research and advanced modeling of tumor regression. Robust protocol parameters and well-characterized limitations support its reliable integration in preclinical workflows.

• Metabolite Regulation of TET2: Protocol Innovation and Insig

  2026-07-20

  Zhang et al. present a robust protocol integrating biochemical assays and STD NMR to dissect metabolite binding and regulatory effects on TET2 dioxygenase. This framework enables precise identification of both activators and inhibitors, advancing our understanding of metabolic-epigenetic interplay and offering a methodological foundation for future studies on enzyme regulation.

• Topotecan HCl (SKU B2296): Reliable DNA Damage Induction in

  2026-07-19

  This authoritative, scenario-driven article addresses common laboratory challenges in cell viability and cytotoxicity assays, demonstrating how Topotecan HCl (SKU B2296) from APExBIO ensures reproducible, data-backed results. Readers gain practical insights into protocol optimization, data interpretation, and product selection, supported by literature and detailed workflow parameters.

• Protease Inhibitor Cocktail (EDTA-Free, 200X in DMSO): Pract

  2026-07-18

  The Protease Inhibitor Cocktail (EDTA-Free, 200X in DMSO) prevents protein degradation during extraction workflows, protecting sample integrity in assays such as Western blotting and co-immunoprecipitation. It is not suitable for experiments requiring metalloprotease inhibition via EDTA or where DMSO sensitivity is a concern.

• L-Glutathione Reduced: Applied Redox Protocols for Cancer Re

  2026-07-17

  L-Glutathione Reduced (SKU B7775) from APExBIO enables highly reproducible workflows in oxidative stress and cancer metabolism research, with robust solubility and proven GST-activity support. This guide translates cutting-edge findings in pancreatic cancer redox biology into actionable assay protocols, troubleshooting, and workflow upgrades.

• Remdesivir (GS-5734): Mechanistic Leverage for Translational

  2026-07-17

  This thought-leadership article explores how Remdesivir (GS-5734) serves as a pivotal tool for translational researchers bridging molecular insight and preclinical antiviral strategy. By integrating recent breakthroughs in viral polymerase structure, benchmarking data, and strategic guidance, it provides a high-impact roadmap for those advancing coronavirus and Ebola virus research.

• Latrunculin A: Reversible Inhibitor of Actin Assembly for Cy

  2026-07-16

  Latrunculin A empowers precise, reversible manipulation of actin dynamics in both in vitro and cellular models. Discover stepwise protocols, troubleshooting insights, and advanced applications driving breakthroughs in cytoskeleton disaggregation and tumor cell research.

• Leonurine Targets Endothelial STING to Halt Doxorubicin Card

  2026-07-16

  This study uncovers that cardiac vascular endothelial cells are the primary sensors and amplifiers of doxorubicin-induced cardiotoxicity, mediated through the cGAS-STING/NF-κB/NLRP3 inflammasome axis. Leonurine, a natural alkaloid, directly inhibits STING at a novel site, disrupting the pathogenic signaling loop and offering a new paradigm for preventing anthracycline-induced heart failure.

446 records 10/30 page Previous Next First page 上5页 678910 下5页 Last page